NDAORALTABLET
Approved
Dec 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYLOREL (guanadrel sulfate) is an oral antihypertensive agent approved in 1982 that works as an adrenergic neuron blocking agent to lower blood pressure. It is indicated for hypertension management in patients who require pharmacological intervention. The drug represents a legacy therapeutic from the early antihypertensive era with a well-established but aging mechanism.
LOE Approaching
With LOE approaching and minimal current commercial activity, this product operates a maintenance-focused team with limited growth trajectory or expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HYLOREL offers minimal career development opportunity; the product is in late-stage lifecycle decline with zero linked job postings and no active growth initiatives. Roles on this team are typically defensive, focused on protecting remaining market share and managing decline rather than driving innovation or expansion.
Brand ManagerRegional Sales Manager
Worked on HYLOREL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.